Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MMP11 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal, Intratumoral, Intrathecal, Subcutaneous, Oral
01
Overview
MMP11 siRNA is a small interfering RNA designed to silence the expression of matrix metalloproteinase 11 (MMP11), also known as stromelysin-3. MMP11 is a member of the matrix metalloproteinase family involved in the degradation of the extracellular matrix and is frequently overexpressed in various cancers, including bladder cancer, where it promotes tumor progression, migration, and invasion. In research settings, MMP11 siRNA is used to investigate the functional role of MMP11 in oncogenic pathways and to validate it as a therapeutic target. Studies have shown that silencing MMP11 can inhibit the migration and invasion of cancer cells, suggesting its potential as a target for RNA interference-based therapies.
- Other names
- matrix metallopeptidase 11 siRNAstromelysin-3 siRNAstromelysin3 siRNAstromelysin 3 siRNA
02
Targets
MMP11 (Matrix metalloproteinase-11 (MMP11) mRNA)
Beyond the preview
Go deeper on MMP11 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MMP11 siRNA.